Phase II Study of Sunitinib Plus Extended Courses of Irradiated Allogeneic Lymphocytes for Patients With Renal Cell Carcinoma (SPECIAL Trial).
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SPECIAL
- 13 Feb 2017 Status changed from active, no longer recruiting to discontinued.
- 26 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 Jun 2012 Planned end date changed from 1 Feb 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.